APA

Hyman D. M., Rizvi N., Natale R., Armstrong D. K., Birrer M., Recht L., Dotan E., Makker V., Kaley T., Kuruvilla D., Gribbin M., McDevitt J., Lai D. W. & Dar M. (20191119). Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Chicago

Hyman David M, Rizvi Naiyer, Natale Ronald, Armstrong Deborah K, Birrer Michael, Recht Lawrence, Dotan Efrat, Makker Vicky, Kaley Thomas, Kuruvilla Denison, Gribbin Matthew, McDevitt Jennifer, Lai Dominic W and Dar Mohammed. 20191119. Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. : Clinical cancer research : an official journal of the American Association for Cancer Research.

Harvard

Hyman D. M., Rizvi N., Natale R., Armstrong D. K., Birrer M., Recht L., Dotan E., Makker V., Kaley T., Kuruvilla D., Gribbin M., McDevitt J., Lai D. W. and Dar M. (20191119). Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. : Clinical cancer research : an official journal of the American Association for Cancer Research.

MLA

Hyman David M, Rizvi Naiyer, Natale Ronald, Armstrong Deborah K, Birrer Michael, Recht Lawrence, Dotan Efrat, Makker Vicky, Kaley Thomas, Kuruvilla Denison, Gribbin Matthew, McDevitt Jennifer, Lai Dominic W and Dar Mohammed. Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors. : Clinical cancer research : an official journal of the American Association for Cancer Research. 20191119.